Literature DB >> 11493447

Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response.

J Levin1, L Cocault, C Demerens, C Challier, M Pauchard, J Caen, M Souyri.   

Abstract

Administration of 5-fluorouracil (5-FU) to mice results in a marked increase in the level of circulating platelets in 10 days. Mice lacking Mpl, the receptor for thrombopoietin (TPO), are thrombocytopenic. To gain insight into the mechanism by which 5-FU produces such a substantial stimulation of platelet production, this study investigated whether 5-FU (150 mg/kg) produced thrombocytosis in c-mpl(-/-) mice, thus establishing whether TPO was required for this response. A 5- to 6-fold increase in platelet levels in c-mpl(-/-) mice (to approximately 1000 x 10(9)/L) was observed on days 20 and 25 after 5-FU injection. Thus, at the peak of the response, c-mpl(-/-) mice had platelet levels comparable to those in normal mice. Administration of 5-FU also produced thrombocytosis in previously splenectomized c-mpl(-/-) mice. Comparison of the platelet response to 5-FU in young (6-12 weeks) and old (33-46 weeks) c-mpl(-/-) mice found that older mice produced a much more marked response than younger mice, with a mean maximum platelet level of approximately 1700 x 10(9)/L. To determine whether this increase in circulating platelets was preceded by an increase in hematopoietic progenitors, serial cultures of bone marrow and spleen were evaluated. A considerable increase in all colony types studied was observed on days 15 and 20 in spleens of c-mpl(-/-) mice, but no similar elevations were detected in bone marrow. These results indicate that c-mpl(-/-) mice can achieve a normal level of platelets after 5-FU injection, by means of a TPO-independent mechanism, and that they respond to 5-FU myelosuppression by producing large numbers of megakaryocytic, myeloid, and erythroid progenitors. (Blood. 2001;98:1019-1027)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493447     DOI: 10.1182/blood.v98.4.1019

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury.

Authors:  Jin Zhou; Jie Li; Daniel M Rosenbaum; Frank C Barone
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

2.  BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors.

Authors:  John M Perry; Omid F Harandi; Robert F Paulson
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

3.  Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.

Authors:  Alison R Moliterno; Donna M Williams; Laura I Gutierrez-Alamillo; Roberto Salvatori; Roxann G Ingersoll; Jerry L Spivak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

4.  Point mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/- mice.

Authors:  Maria Kauppi; James M Murphy; Carolyn A de Graaf; Craig D Hyland; Kylie T Greig; Donald Metcalf; Adrienne A Hilton; Nicos A Nicola; Benjamin T Kile; Douglas J Hilton; Warren S Alexander
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

5.  Terminal platelet production is regulated by von Willebrand factor.

Authors:  Sonia Poirault-Chassac; Kim Anh Nguyen; Audrey Pietrzyk; Caterina Casari; Agnes Veyradier; Cecile V Denis; Dominique Baruch
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

6.  A numerical analysis model for the interpretation of in vivo platelet consumption data.

Authors:  Ted S Strom
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

7.  Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS.

Authors:  Amaya Rando; Miriam de la Torre; Anna Martinez-Muriana; Pilar Zaragoza; Antonio Musaro; Sara Hernández; Xavier Navarro; Janne M Toivonen; Rosario Osta
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

8.  Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Authors:  Jerry L Spivak; Akil Merchant; Donna M Williams; Ophelia Rogers; Wanke Zhao; Amy Duffield; Linda S Resar; Alison R Moliterno; Zhizhuang J Zhao
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.